Radium-223 chloride: Radiation safety, tolerability, and survival gain in patients with castration-resistant prostate cancer (CRPC) and bone metastases

被引：0
|
作者：
Lewington, Valerie [1 ]
Lamey, Roy [2 ]
Staudacher, Karin [3 ]
Vogelzang, Nicholas [2 ]
机构：
[1] Guys & St Thomas Hosp, London, England
[2] Comprehens Canc Ctr Nevada, US Oncol Res, Las Vegas, NV USA
[3] Algeta ASA, Oslo, Norway
来源：
JOURNAL OF NUCLEAR MEDICINE | 2012年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
222
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Radiation safety, tolerability, and survival gain in patients with castration-resistant prostate cancer (CRPC) and bone metastases receiving radium-233 chloride in a double-blind, randomized, phase III trial (ALSYMPCA)
    Lewington, V.
    Lamey, R.
    Staudacher, K.
    Vogelzang, N.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S304 - S304
  • [22] Radium-223 Dichloride: A Novel Treatment Option for Castration-Resistant Prostate Cancer Patients With Symptomatic Bone Metastases
    McGann, Shane
    Horton, Evan R.
    ANNALS OF PHARMACOTHERAPY, 2015, 49 (04) : 469 - 476
  • [23] Radium-223 Dichloride: A Review of Its Use in Patients with Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases
    Matt Shirley
    Paul L. McCormack
    Drugs, 2014, 74 : 579 - 586
  • [24] Radium-223 Dichloride: A Review of Its Use in Patients with Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases
    Shirley, Matt
    McCormack, Paul L.
    DRUGS, 2014, 74 (05) : 579 - 586
  • [25] Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: A phase III randomized trial (ALSYMPCA)
    Sartor, A. Oliver
    Heinrich, Daniel
    Helle, Svein Inge
    O'Sullivan, Joe M.
    Fossa, Sophie D.
    Chodacki, Ales
    Demkow, Tomasz
    Logue, John P.
    Seke, Mihalj
    Widmark, Anders
    Johannessen, Dag Clement
    Nilsson, Sten
    Hoskin, Peter
    Solberg, Arne
    James, Nicholas David
    Syndikus, Isabel
    Vogelzang, Nicholas J.
    O'Bryan-Tear, C. Gillies
    Shan, Minghua
    Parker, Chris
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [26] Phase II Clinical Study of Radium-223 Chloride (BAY 88-8223) in Japanese Patients With Symptomatic Castration-Resistant Prostate Cancer (CRPC) With Bone Metastases
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (04) : 14 - 15
  • [27] Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: A phase III randomized trial (ALSYMPCA)
    Miller, K.
    Sartor, A. O.
    Heinrich, D.
    Helle, S., I
    O'Sullivan, J. M.
    Fossa, S. D.
    Chodacki, A.
    Demkow, T.
    Logue, J. P.
    Seke, M.
    Widmark, A.
    Johannessen, D. C.
    Nilsson, S.
    Hoskin, P.
    Solberg, A.
    James, N. D.
    Syndikus, I
    Vogelzang, N. J.
    O'Bryan-Tear, C. G.
    Shan, M.
    Parker, C.
    ONKOLOGIE, 2012, 35 : 238 - 239
  • [28] Dosimetry, imaging and administration of radium (Ra) 223 dichloride in patients with castration-resistant prostate cancer (CRPC) and bone metastases
    Flux, Glenn
    Chittenden, Sarah
    Pratt, Brenda
    Hindorf, Cecilia
    Parker, Chris
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2013, 56 : S51 - S51
  • [29] Phase 3 study of radium-223 dichloride (Ra-223) in Asian patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets)
    Sun, Y.
    Shi, H.
    Chen, C. -H.
    Lee, J. L.
    Kang, T. W.
    Park, S. H.
    Wu, T. L.
    Ng, Q. S.
    Keam, B.
    Wong, S. C. A.
    Tay, M. H.
    Ding, Q.
    Li, F.
    Ng, D. C. E.
    Liu, X.
    Zhang, Z.
    Guo, J.
    ANNALS OF ONCOLOGY, 2015, 26 : 73 - 74
  • [30] Radium-223 dichloride in castration-resistant prostate cancer with symptomatic bone metastases: a guide to its use
    Shirley M.
    McCormack P.L.
    Drugs & Therapy Perspectives, 2016, 32 (3) : 98 - 103
12345